Background. The Early Lung Cancer Action Project (ELCAP) is designed to evaluate baseline and annual repeat screening by low-radiation-dose computed tomography (low-dose CT) (Lancet 1999;354:99-105) 
Lung cancer is common, fatal if untreated, and remortality we need to intercept more patients much earlier, ideally with stage I disease, from an asymptosponsible each year for more deaths in the USA and Western Europe than colorectal, cervical, and breast matic at risk population. The screening tools of chest radiography and sputum cytology are safe, effective, cancer combined.
1 Those most at risk are current smokers, but rates of lung cancer remain high many cheap, and available and yet -in contrast to colorectal, cervical, and breast cancer -there are currently no years after smoking cessation 2 with estimates of 92 million ex-smokers at risk of the disease in the USA screening programmes for early detection of stage I lung cancer. Why not? Four randomised control trials (RCTs) alone. This means that, in the unlikely event that a combination of education and public health policies screening male smokers in the 1970s all failed to show a reduction in mortality from lung cancer, [12] [13] [14] [15] [16] [17] [18] [19] and the make smoking a sin of the past, the scourge of lung cancer will still be with us for the foreseeable future.
nihilistic mantra that screening for lung cancer does not work has taken hold. Currently, even though common Despite the high incidence of lung cancer, up to date treatments have had no worthwhile impact on the sense and clinical experience argue that early detection and treatment of lung cancer is advantageous, no adgloomy five year survival figure of 7-13%, [3] [4] [5] [6] which has remained unchanged for 30 years. Cure rates are highly visory committee recommends mass screening of at risk patients. Three decades on, it is remarkable that these dependent on tumour staging. If patients present early with resectable stage I disease, five year survival can be RCTs, with their own shortcomings, have been so powerful in dismissing the potential of screening. It is as high as 70%. [7] [8] [9] [10] [11] However, the presenting symptoms of lung cancer occur late in the natural history of the refreshing, timely, and appropriate that recent interest in the use of helical computerised tomographic (CT) illness, with up to 80% of patients having unresectable advanced disease and only 20% of lung cancers being scanning and biomedical markers of early malignant change have rekindled an interest in screening for lung picked up as stage I growths. 3 To improve lung cancer cancer and a review of the prevailing dogma that screen-15% in the screened and control groups, respectively. Just as in the Mayo project, five year survival in the ing does not save lives. The Early Lung Cancer Action Project (ELCAP) study (the introductory article) 20 and patients diagnosed with lung cancer was significantly better in the screened group (23% versus 0%, p= a recent Japanese study that also used CT screening 21 aim to establish a curability rate based on the size of 0.0001). However, lung cancer mortality was higher in the screened group after three years (28 versus 18 lung cancers detected by screening. The hope is that, if the percentage of lung cancers detected at stage I can deaths). After six years there were 108 cases of lung cancer (85 deaths) in the screened group and 82 lung be increased from the current figure of 20%, mortality advantages will follow. If so, then an RCT to examine cancers (67 deaths) in the control group, an insignificant difference in lung cancer mortality (p=0.16). Again, as whether widespread screening for lung cancer is justified would be an urgent priority in the fight against this for the Mayo Lung Project, although there were benefits in stage distribution, curability and disease specific fatdisease.
ality in the screened group, these did not translate into decreased mortality from lung cancer, the only end point deemed free from bias. The past -the 1970s: paving the way for nihilism In the 1970s, with increasing rates of lung cancer in the USA, the National Cancer Institute (NCI) sponsored three large RCTs in the context of the Cooperative     Johns Hopkins Hospital 13 18 and Memorial-SloanEarly Lung Detection Program; a fourth RCT took place in Czechoslovakia.
Kettering Hospital 17 22 both randomised male smokers over the age of 45 to undergo annual chest radiographic examination and three day pooled sputum cytology every four months while a control group underwent     The Mayo Lung Project 12 15 16 18 compared regular only annual chest radiography. Neither hospital showed any benefit to lung cancer mortality from the addition screening with infrequent, sporadic, or no screening in a control group. The participants were men aged 45 or of sputum cytological examination. Less than 10% of cancers were detectable by sputum cytology alone which older who had smoked 20 cigarettes or more a day for the year before entry to the study. Prevalent cases of might reflect the poor sensitivity of sputum cell morphological studies that were available at the time. Inlung cancer were excluded by chest radiography and three day pooled sputum cytological examination. The terestingly, the stage distributions and five year survival of all men who developed lung cancer were more fascreening group underwent chest radiography and sputum cytology every four months for six years whilst the vourable than the national average (35% versus 13%). 8 control group were given the "standard Mayo advice" of the time which was to have an annual chest radiograph and sputum cytological examination. Patients were not      Although all four were RCTs, only the Mayo Lung reminded of this advice. The experimental and follow up period lasted for an average of nine years in total.
Project had a true control group that was unscreened. The design of the Mayo trial was such that it lacked At the conclusion of the study 160 of 4595 cancers were detected in the control group (none through selfpower from the outset with less than 20% power to detect a 10% benefit in lung cancer mortality and 55% referral for screening chest radiographs) and 206 of 4618 in the screened group (44% of which were picked power to detect a 20% benefit. This lack of power was increased even further by contamination of the control up during screening studies rather than as a result of symptoms), giving a cumulative incidence of lung cancer group, of whom 55% had had a chest radiograph in the last year and 73% in the final two years. In addition, in experimental and control populations of 4.5% and 3.5%, respectively. The number of deaths from lung compliance between the groups was low at 75% for the screened and 50% for the control group. As well as cancer, the death rate from lung cancer per 1000 person years, and the all-cause mortality were unaffected by being a weak study, the screening regime appeared inexplicably ineffectual. Over the screening period only screening. This led to the conclusion that differences between the two groups could be explained by lead time 45 of 206 lung cancers (22%) picked up in the screened group were resectable compared with a 60% resectbias, length biased sampling, and/or overdiagnosis. The paradox that a favourable shift in stage distribution ablility of the lung cancers picked up in both groups at baseline. Given that so many problems and criticisms did not translate into an improvement in lung cancer mortality remained unexplained.
have been waged at this study, it is even more remarkable that public health policy has been so influenced by it.
     
The Czechoslovakian lung cancer screening study en-         rolled male smokers aged 40-64 years with a life time cigarette consumption of approximately 20.5 pack
Of enormous interest and importance is the significant excess of diagnosed lung cancers in the screened group years.
19 Prevalent cases were excluded by chest radiography and 24 hour sputum cytological examination.
in the Mayo Lung Project (p=0.016; mainly early stage, resectable squamous cell carcinomas plus early stage The screened group had chest radiographs and sputum cytological screening every six months for three years and some advanced adenocarcinomas) which also approached significance in the Czechoslovakian study (p= whilst the controls had a single screen at the end of the study. Both groups then had chest radiographs annually 0.065). Given that there is no evidence that the level of screening radiation was harmful, the excess must reflect for three further years. At the end of the three year study period, before the final three year radiograph, 36 a problem with study design such as misdiagnosis, overdiagnosis in the study group (finding lung cancers lung tumours had been identified in the study group (75% of which were picked up through screening) and that would never be clinically important), underdiagnosis in the control group, or population hetero-19 in the control group. Resectability was 25% and geneity. Epidemiological data and the biological three groups on the basis of smoking history (current smoker, former smoker, and never smoked) to be virulence of lung cancer argue that indolent lung cancers are vanishingly rare and overdiagnosis is therefore unscreened or not screened. The screening for lung cancer will involve an annual chest radiograph. The study has likely to explain the difference. Incorrect diagnosis is a better candidate; not all of the cancers were diagnosed an estimated power of 0.89 to detect a difference in lung cancer mortality of 10% and a power of 0.99 to by thoracotomy and necropsy and some labelled as primary lung cancers might have been, for example, pick up a difference of 20%. Although the design will overcome some of the deficiencies of earlier studies, the metastatic adenocarcinomas. Underdiagnosis in the control group is certainly possible if participants died problems of population heterogeneity and confounding risk factors may still not be adequately controlled. of competing disease before diagnosis of their lung cancer, and this is likely because of the high rates of coexistent cardiovascular disease in these populations. However, none of these diagnostic inaccuracies can        Although there is renewed interest in chest radiographic explain the increase in "missing cases" in the follow up period of the Czechoslovakian study when control and screening, information since the Mayo trial suggests that this is an insensitive tool. The chest radiograph is screened groups were treated as one, and all underwent annual chest radiography. The only explanation for a especially inadequate at picking up those lesions for which early detection is most beneficial -that is, lesions continued difference in lung cancer between the two populations is that there were uncontrolled differences of 2 cm in size, stage I adenocarcinomas, and rapidly growing small cell and squamous cell carcinomas. 31 between them all along. Asbestos exposure, 23 radon exposure, 24 chronic obstructive pulmonary disease, 25 Recognition of this fundamental limitation inspired the search for other screening methods. Meanwhile, techand genetic background 26 27 all affect lung cancer rates in smokers, even after controlling for cigarette connological advances produced the helical (or spiral) CT scan with an estimated potential to detect 80-85% of sumption. In reality, the excess lung cancer cases can be explained by invoking a combination of inaccurate lung cancers at stage I. 32 In the past CT scanning was disregarded for lung cancer screening because of diagnoses and population heterogeneity, and further question the design of these studies. 28 problems with availability, acceptability, and expense. Computed tomography delivers a high radiation dose and the images produced require lengthy specialist interpretation with a higher cost-benefit ratio than plain      chest radiography. This perception has altered dramatically with the introduction of fast, low dose (50 Disease specific mortality is the gold standard for evaluating the effects of screening within an RCT as it is mA), spiral CT scanners which produce a radiation dose one sixth that of a conventional CT scanner and the only end point not affected by lead time bias, length time bias, or overdiagnosis. In the context of an RCT, only 10 times that of chest radiography. 32 Screening takes 20 seconds, no contrast is used, and the cost is inaccurate or underdiagnosis does not affect the mortality end point but will affect the disease specific moronly slightly more than a chest radiograph. 32 33 The International Commission of Radiological Protection tality. Population heterogeneity has a much more sinister effect. The RCT requires generation by randomisation estimates the nominal fatal cancer risk factor to be 5 × 10
/mSv so that the estimated risk of causing a fatal of two equivalent groups with an equivalent risk of dying from a certain disease. If large enough, the groups will cancer for an effective dose of 0.9-1.5 mSv is calculated at about one in 26 000 person years. An even newer be comparable both for known and for unrecognised confounding variables. If randomisation produces two development is the ultra low dose mobile scanner of −6 mA (resolution falls off at 3 mA). 34 groups that differ in disease incidence, mortality comparisons between the two groups become impossible. The increasing availability of low dose spiral CT scanning at a time when trials for early lung cancer Comparisons have even less meaning if the disease incidence between the heterogeneous groups is low. detection were undergoing re-evaluation in the light of recognised limitations of trial design and screening Compare the groups in a clinical trial in which everyone has the disease and are only a short time from diagnosis methods paved the way for two key projects in the 1990s. Both of these studies were designed to evaluate with those in a screening trial in which no one has the disease and only 1-5% will get it. A small difference of the role of low dose spiral CT scanning in the early detection of lung cancer. The study by Sone and col-1% in the total incidence in the Mayo Lung Project translates into a greatly increased proportional incidence leagues in Matsumoto, Japan presented preliminary data from the first RCT of low dose spiral CT scanning as of 20-40% in disease specific incidence. Small differences in disease incidence and mortality can therefore a mass screening tool, 21 and last year saw the publication of the first report from the Early Lung Cancer Action be grossly misinterpreted if the two groups are not adequately matched.
Project (ELCAP) in which Henschke and colleagues presented their study design and results of baseline screening.
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The present -a new millennium: renewed enthusiasm          The first and only RCT to compare mobile CT scanning The Prostate, Lung, Colon and Ovarian (PLCO) Study is an RCT funded by the National Cancer Institute and chest radiography in mass screening for early lung cancer was set up in 1996 to screen a Japanese poputhat aims to evaluate the role of screening in reducing mortality from these four common neoplasms. 29 30 The lation at low risk of the disease. 21 A mobile, low dose, helical CT scanner (50 mA, without contrast) was used study was set up to address some of the concerns raised over the design and interpretation of previous cancer to screen unselected volunteers. These were smokers and non-smokers aged 40-74 years who had already screening trials and aims to recruit 148 000 men and women aged 60-74 years. They will be randomised into undergone annual chest radiography (miniature fluoro-photography) and sputum cytology as part of a national recommendations for the classification and further investigation of non-calcified nodules (NCNs) which inscreening programme. Of the participants, 3967 underwent both miniature fluorophotography and low dose cluded a short term follow up high resolution CT scan for the smallest NCNs. At the initial screening low dose helical chest CT scanning, and each was matched with two controls from the same population who underwent CT scanning picked up NCNs in 233 participants (compared with 68 identified by chest radiography). All miniature fluorophotography only. Smokers from both groups underwent cytological examination of a 72 hour 233 then underwent conventional helical CT scanning and biopsy samples were taken from 28 subjects, of sputum collection. Each CT scan was read by one of four radiologists who classified the abnormalities. which 27 were malignant (PPV 27/233; 11.6%). Of these, 18 were adenocarcinomas and there were no Participants with suspicious lesions (59/3967, 1%), indeterminate nodules (80/3967, 2%), and suspected cansmall cell lung cancers. Stage I carcinomas made up 23 of the 27 tumours of which only four were visible on cer (84/3967, 2%) were followed up with conventional chest radiography, high resolution CT scanning, and the chest radiograph and 26 (96.3%) were resectable. This last figure compares dramatically with the retransbronchial biopsy where possible. Of the 3967 participants, 223 underwent further examinations and 19 sectability of only 30 of the 59 cancers that were picked up in the Mayo Project at baseline chest radiographic (0.48%) were diagnosed with histologically confirmed lung cancer. In only one of the 19 patients was the screening. Malignant disease was also found by low dose CT scanning in four other participants -endobronchial abnormality seen on miniature fluorophotography and correctly interpreted, eight had abnormalities on chest disease in two and mediastinal in the other two. These were not included in the quantitative analysis as the radiography, and one other on a lateral view. High resolution CT scanning missed one central carcinoma study was examining nodules. Again, the prevalence of malignant disease (31 per 1000) was higher than that was picked up by sputum cytology. This gives an initial sensitivity for the protocol of 0.95 which will expected. presumably decrease as missed cancers become apparent. Of the 19 cancers, 16 were American Joint Committee stage I and three were stage IV; 12 of the 19 were peripheral adenocarcinomas. Although large      Both these studies 20 21 raise issues of sensitivity and numbers of participants were screened and underwent further investigation, the pick up rate for cancer was specificity. The number of malignancies picked up at initial screening in both studies is higher than expected, relatively low giving a positive predictive value (PPV) of 8.5% (19/223). The lung cancer incidence of five per with a striking preponderance of adenocarcinomas and an absence of small cell carcinomas. This has raised the 1000 people screened was much greater than expected for the population (×2.6 for men and ×15.7 for question of whether these peripheral adenocarcinomas, which are not easily seen on chest radiographs and may women) and, strikingly, there was no difference in lung cancer rates between smokers and non-smokers. Albe very slow growing, are clinically relevant. In addition, Sone et al found no difference in the rate of lung cancer though the results may seem encouraging, it is worth bearing in mind that, to find 16 resectable cancers, 223 between smokers and non-smokers. These findings raise the possibility that small cell lung cancers detected by participants were examined with chest radiography, high resolution CT scanning, and some with transbronchial CT scanning have a different tumour biology from stage I lung cancers detected by chest radiography which may biopsy, 204 of whom did not have anything wrong. This has obvious implications in health care planning and be altered further by smoking. Another possibility is that the higher incidence of lung cancers in the Mateconomics. Mortality data comparing the screened population with their matched controls is not yet availsumoto study simply reflects those tumours missed by the previous year's annual screen. If this is the case, able but will be presented at the end of a one year follow up period.
then the incidence figures in subsequent years will return to expected levels and would strongly suggest that the tumours are all biologically relevant but, because they are picked up earlier, they are over-represented in the       () ELCAP was initiated in 1992 as a non-comparative trial initial screen. This explanation would be supported if the ELCAP's one year follow up shows that a large to allow fast and cost effective collection of information with two main aims. The first was to establish the role proportion (for example, 30-40%) of new nodules are malignant, a finding that would increase the PPV of of annual low dose helical CT scanning in the diagnosis of early lung cancer by the evaluation of pulmonary subsequent screens from that of the original baseline value. Given the lack of small cell carcinomas in the nodules (as opposed to large central lesions). 20 This involved the screening of high risk participants to docuinitial screen despite an expected incidence of 20%, 3 it will be interesting to see the cell types of these new ment the incidence of pulmonary nodules as detected by CT scanning and is to be complemented by follow nodules. These data, together with information on cost effectiveness, will be published later this year. Another up data on rates of malignancy and resectability and, ultimately, on the relation between nodule size at deworry, especially given the absence of certain cell types, is the potential problem of underdiagnosis if lung nodules tection and survival and cure. The second aim was to use this data base as a gold standard against which other were incorrectly classified as benign and biopsy samples were not taken. Any missed cancers will become apstudies of early lung cancer detection such as biomedical screening tools could be compared. The study recruited parent provided the follow up period is long enough. The one year follow up suggested for the study by Sone 1000 symptom free volunteers who were at a higher risk of lung cancer than in the Matsumoto study. The et al is too short and should be extended to allow proper data on sensitivity to be collected. It is hoped that these entry age was 60 years or over with a smoking history of at least 10 pack years (median 45 pack years), and data will be provided by the ELCAP but may take some time. Also of concern is that 70% of all lung cancers subjects had to be deemed fit for thoracotomy. Each participant underwent chest radiography and low dose arise in the large proximal airways and are visible at bronchoscopy, but the CT based studies have focused helical CT scanning (40 mA). ELCAP laid down specific
potential is the finding of volatile organic compounds (VOCs), particularly alkanes and benzene derivatives, regular follow up will provide data on the incidence and detection of the more common central tumours.
in the breath of patients with lung cancer. 35 As such, these new techniques may complement low dose helical CT imaging which is less lung cancers using low dose helical CT scanning at enrolment and annually for three years thereafter. By sensitive for detecting central tumours and premalignant changes. One cell surface marker is the heterogeneous December 1500 individuals had been enrolled; they were 50 years of age, current or former smokers (>20 nuclear ribonucleoprotein (hnRNP) A2/B1 which is upregulated on premalignant bronchial epithelial cells.
pack years), not on supplemental oxygen, and with a life expectancy of more than five years. The aim is to In a pilot study of sputum archived from the Johns Hopkins screening study, overexpression of A2/B1 was detect 75% or more of lung cancers at stage I (J R Jett, personal communication). In Florida another pilot study a more sensitive marker of early preinvasive malignancy than normal cytological screening (sensitivity 91%, has started using helical CT scanning and sputum screening with hnRNP A1/B2 analysis. This study aims specificity 88%). In fact, features of malignancy were identifiable about one year before the conventional cytoto screen 5000 men of high risk and, as lung cancer is more common in those with airflow obstruction, 51 all logical examination showed abnormalities or the tumour was visible on the chest radiograph. 36 37 Similar enthose with a forced expiratory volume in one second (FEV 1 ) of <70% predicted (about 23% of those couraging results have been shown in prospective trials of Chinese tin miners, 38 North American lung cancer screened) will be enrolled. Subjects will be >45 years of age and have smoked >30 pack years and the aim is patients who have undergone resection of their primary tumour but are at high risk of recurrent disease, 37 39 to detect a threefold increase in stage I cancer (M S Tockman, personal communication). Other groups in and UK patients under investigation for lung cancer. 40 Another approach has been to look at early chromosomal Germany, Israel, and possibly the UK 52 are considering establishing their own studies. and genetic alterations in lung epithelial cells. In a retrospective study Mao et al found that point mutations in the p53 and K-ras genes in sputum samples preceded the clinical diagnosis of lung cancer in one case by more , ,    There are many issues that arise from the activity dethan one year. 41 Other groups have identified areas of genomic instability which cause microsatellite alterscribed in this review. Analysis of the data of the 1980s suggests flaws both in study design and interpretation, ations that can act as clonal markers of early malignant disease. 42 but there have been substantial developments in technology, therapeutics, and methodology since then. At The limitations of sputum examination have led to the development of more invasive procedures to retrieve present all the effort is focusing on the value of helical CT scanning (together with biological markers in the samples for biomedical analysis. Whilst fibreoptic bronchoscopy with white light may be used to detect presputum in some studies) and it is emerging that the incidence of stage I cancers probably will rise to 60% invasive lung cancers, examination with fluorescent light greatly increases the detection of non-invasive cancers of those identified. However, different groups have different algorithms for dealing with NCNs and only and precursor lesions. [43] [44] [45] Similarly, although the distal lung cannot be visualised bronchoscopically, the perisome are following the Henschke guidelines. Hence, this, together with the inevitable learning curves (the pheral airways can be sampled using bronchoalveolar lavage (BAL). The predominant cells retrieved following more multicentred a trial, the more difficult this becomes), will make interpretation less certain. BAL are alveolar macrophages and lymphocytes and the relative numbers of epithelial cells are small. These A more important issue is the selection of the group to screen. Sone et al 21 screened a large cohort of relatively cells can then be subject to the same screening tests applied to expectorated sputum or lavage fluid. young smokers and non-smokers and identified far fewer cancers than Henschke et al 21 who screened 1000 older There is also evidence that microsatellite abnormalities can be detected in the plasma of patients with localised committed smokers. Others are going further by including the presence of airflow obstruction. The choice non-small cell lung carcinomas but not in controls, which gives the exciting prospect of using a blood test of population to screen will have a profound effect on cost, and the economic factor is of major concern. to screen for lung cancer. 48 However, although these tests are highly specific, their sensitivity is low and A move to routine screening would represent a fundamental change in our approach to lung cancer. Standleast helpful in patients with small, peripherally located, tumours and, as yet, are not appropriate for screening ard CT scans without contrast cost £500 at University College London Hospitals. If we assume that there are purposes. 49 One further interesting observation with screening 12.1 million adult smokers in the UK (and many more 
